Fig. 2.

Treatment with CXCL1 neutralizing antibody reduced retinal thickening, inflammation, ROS, and vascular dysfunction in Ang II-infused mice.

(A) WT C57BL/6J mice were treated with IgG control or CXCL1 neutralizing antibody (anti-CXCL1, 100 μg/mouse/day) and then infused with Ang II for three weeks. Images of H&E staining of central retinal sections (left) and quantitation of the retinal thickness (right, n = 8). (B) Typical retinal angiograms and fundus photos (left); these white arrows indicate vascular fluorescein leakage and the corresponding area in the fundus photo. The ratio of retinal arteriovenous and fluorescence intensity was quantified (right; n = 6). (C) Retinal superoxide production was evaluated by DHE staining (left); the red fluorescence intensity of DHE was quantified (right; n = 6). (D) Waveforms of oscillatory potential (left) and amplitude quantification (right; n = 6). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)